News

Hypoparathyroidism is often temporary in children who undergo surgical removal of the thyroid, or thyroidectomy, with most recovering normal parathyroid function within six months, a study in China shows. The time needed to recover from hypoparathyroidism was found to be closely related to the levels of parathyroid hormone (PTH)…

A Phase 2 clinical trial testing MBX 2109 in people with chronic hypoparathyroidism has finished enrolling participants, according to MBX Biosciences, the treatment’s developer and sponsor of the trial. “Completion of enrollment in our Phase 2 trial in [hypoparathyroidism] marks a significant milestone for MBX and brings us closer…

Yorvipath (palopegteriparatide) has been approved in Australia as a parathyroid hormone (PTH) replacement therapy for adults with chronic hypoparathyroidism. The news follows similar approvals in the European Union in 2023, and in the U.S. last year. Yorvipath will be made available in Australia through Specialised Therapeutics, under…

To help people with hypoparathyroidism in the U.S. who are facing out-of-pocket medical costs, The Assistance Fund (TAF) — a nonprofit launched in 2009 to aid individuals with a range of health conditions — has opened a program for patients and families living with the rare disease. This…

Weekly treatment with MBX 2109, an experimental hormone replacement that MBX Biosciences is developing for chronic hypoparathyroidism, appears to be long-acting and to mimic natural parathyroid hormone (PTH) in healthy adults. Data come from a Phase 1 clinical trial (NCT05158335) where side effects reported with multiple doses…

Note: This story was updated Dec. 16, 2024, to correct errors in terminology from hyperparathyroidism to hypoparathyroidism. Reactive supplement use — giving oral supplements of calcium and vitamin D after total thyroidectomy, or the complete surgical removal of the thyroid gland — is safe and effective in patients experiencing…

People with hypoparathyroidism due to surgery have reduced levels of corticosteroids, or hormones produced by the adrenal gland, despite adequate treatment with calcium and vitamin D supplementation, a small study reported. Data showed that short-term replacement parathyroid hormone (PTH) therapy partly restored these hormones to normal levels. Low hormone…

Dosing is underway in a Phase 2 clinical trial of MBX 2109, an investigational hormone replacement therapy for people with hypoparathyroidism, according to the therapy’s developer, MBX Biosciences, with top-line expected around mid-2025. The trial, called Avail (NCT06465108), is evaluating the safety, effectiveness, and pharmacological properties…

Permanent hypoparathyroidism, which can occur when the parathyroid glands are accidentally removed along with the thyroid gland during a surgical procedure, increases the risk of kidney damage over time, according to a study by researchers in Hong Kong. “Careful patient selection and improvement in the identification and preservation of…

The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma’s Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism. The company expects to have the first supply ready in early 2025 after it completes manufacturing for the U.S. market. But if the FDA clears…